Blog Exposure - Endo International to Acquire Some
Post# of 109
(Total Views: 797)
Posted On: 04/30/2018 9:35:57 AM
Blog Exposure - Endo International to Acquire Somerset Therapeutics and its Affiliate Wintac Ltd
LONDON, UK / ACCESSWIRE / April 30, 2018 / Active-Investors.com has just released a free research report on Endo International PLC (NASDAQ: ENDP). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ENDP as the Company's latest news hit the wire. On April 26, 2018, the Company announced that it has inked an agreement to acquire New Jersey-based Somerset Therapeutics, LLC, and its affiliated contract developer and manufacturer in India, Wintac Ltd, for approximately $190 million. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Endo International most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=ENDP
Strategic Benefits
Somerset Therapeutics' portfolio includes eight commercial products as well as a pipeline of more than 40 products, over 25 of which have been submitted for approval to the US Food and Drug Administration (FDA). With this acquisition, Endo significantly increases the number of filed injectable applications. Together, the acquisitions will secure for Endo's Par Sterile injectable business, Somerset Therapeutics' commercial, and pipeline products as well as Wintac's manufacturing capabilities for those products.
Deal Details
Following the acquisition, Somerset Therapeutics will become a wholly-owned subsidiary of Par Pharmaceutical, Inc. and the Wintac's business will become part of Par Formulations Private Limited.
The transaction, expected to close by the end of 2018, is subject to requisite regulatory approvals in the US and India and customary closing conditions.
K&L Gates and Shardul Amarchand Mangaldas & Co. are acting as Endo's legal counsel.
Acquisition Expands Endo's Portfolio of Sterile Injectable and Ophthalmic Products
Commenting on the acquisition, Paul Campanelli, President and Chief Executive Officer of Endo, stated that the Company believes Somerset Therapeutics is an ideal strategic fit for Endo as it expands its portfolio of sterile injectable and ophthalmic products.
According to him, Wintac's strong sterile R&D and high-quality manufacturing capabilities have contributed greatly to Somerset Therapeutics' steady revenue growth.
Paul added that Endo sees significant opportunities to leverage its existing sales and marketing capabilities as it seek to maximize the value of the current and expected future Somerset Therapeutics' products.
Par Pharma Well-Suited to Move Somerset Therapeutics and Wintac's Business to Next Stage of Development
Dr. Veerappan Subramanian, Chairman and CEO of Somerset Therapeutics, mentioned that Par Pharma has deep experience in the growing US sterile injectable drugs market. According to Mr. Subramanian, they are well-suited to move Somerset Therapeutics and Wintac's business to the next stage of development and growth.
Dr. Veerappan added that Somerset Therapeutics is happy to become a part of Endo and Par Pharma, a company it has successfully collaborated with in the past.
About Endo International PLC and Par Pharmaceutical, Inc.
Endo International PLC is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization. Endo has global headquarters in Dublin, Ireland, and US headquarters in Malvern, Pennsylvania.
Par Pharmaceutical, headquartered in Chestnut Ridge, New York, develops, manufactures and markets safe, innovative, and cost-effective generic pharmaceutical products. Par Pharma possesses a portfolio that includes sterile injectables, alternative dosage forms, and many other differentiated products. Endo International PLC acquired Par Pharma in 2015.
About Somerset Therapeutics
Founded in 2015 and headquartered in New Jersey, Somerset Therapeutics is a sterile pharmaceutical company that manufacturers and markets injectable and ophthalmic drugs for the US marketplace. Its Bangalore, India affiliate, Wintac Ltd, operates an FDA-inspected sterile manufacturing facility with proven sterile injectable and ophthalmic R&D capabilities.
Stock Performance Snapshot
April 27, 2018 - At Friday's closing bell, Endo International's stock climbed 6.95%, ending the trading session at $6.00.
Volume traded for the day: 6.03 million shares, which was above the 3-month average volume of 5.10 million shares.
Stock performance in the last month – up 2.74%
After last Friday's close, Endo International's market cap was at $1.34 billion.
The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Other industry. This sector was up 0.4% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author"
and is fact checked and reviewed by a third-party research service company (the "Reviewer" represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor" , provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
Source: ACCESSWIRE Investor Awareness (April 30, 2018 - 7:40 AM EDT)
News by QuoteMedia
www.quotemedia.com
LONDON, UK / ACCESSWIRE / April 30, 2018 / Active-Investors.com has just released a free research report on Endo International PLC (NASDAQ: ENDP). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ENDP as the Company's latest news hit the wire. On April 26, 2018, the Company announced that it has inked an agreement to acquire New Jersey-based Somerset Therapeutics, LLC, and its affiliated contract developer and manufacturer in India, Wintac Ltd, for approximately $190 million. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Endo International most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=ENDP
Strategic Benefits
Somerset Therapeutics' portfolio includes eight commercial products as well as a pipeline of more than 40 products, over 25 of which have been submitted for approval to the US Food and Drug Administration (FDA). With this acquisition, Endo significantly increases the number of filed injectable applications. Together, the acquisitions will secure for Endo's Par Sterile injectable business, Somerset Therapeutics' commercial, and pipeline products as well as Wintac's manufacturing capabilities for those products.
Deal Details
Following the acquisition, Somerset Therapeutics will become a wholly-owned subsidiary of Par Pharmaceutical, Inc. and the Wintac's business will become part of Par Formulations Private Limited.
The transaction, expected to close by the end of 2018, is subject to requisite regulatory approvals in the US and India and customary closing conditions.
K&L Gates and Shardul Amarchand Mangaldas & Co. are acting as Endo's legal counsel.
Acquisition Expands Endo's Portfolio of Sterile Injectable and Ophthalmic Products
Commenting on the acquisition, Paul Campanelli, President and Chief Executive Officer of Endo, stated that the Company believes Somerset Therapeutics is an ideal strategic fit for Endo as it expands its portfolio of sterile injectable and ophthalmic products.
According to him, Wintac's strong sterile R&D and high-quality manufacturing capabilities have contributed greatly to Somerset Therapeutics' steady revenue growth.
Paul added that Endo sees significant opportunities to leverage its existing sales and marketing capabilities as it seek to maximize the value of the current and expected future Somerset Therapeutics' products.
Par Pharma Well-Suited to Move Somerset Therapeutics and Wintac's Business to Next Stage of Development
Dr. Veerappan Subramanian, Chairman and CEO of Somerset Therapeutics, mentioned that Par Pharma has deep experience in the growing US sterile injectable drugs market. According to Mr. Subramanian, they are well-suited to move Somerset Therapeutics and Wintac's business to the next stage of development and growth.
Dr. Veerappan added that Somerset Therapeutics is happy to become a part of Endo and Par Pharma, a company it has successfully collaborated with in the past.
About Endo International PLC and Par Pharmaceutical, Inc.
Endo International PLC is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization. Endo has global headquarters in Dublin, Ireland, and US headquarters in Malvern, Pennsylvania.
Par Pharmaceutical, headquartered in Chestnut Ridge, New York, develops, manufactures and markets safe, innovative, and cost-effective generic pharmaceutical products. Par Pharma possesses a portfolio that includes sterile injectables, alternative dosage forms, and many other differentiated products. Endo International PLC acquired Par Pharma in 2015.
About Somerset Therapeutics
Founded in 2015 and headquartered in New Jersey, Somerset Therapeutics is a sterile pharmaceutical company that manufacturers and markets injectable and ophthalmic drugs for the US marketplace. Its Bangalore, India affiliate, Wintac Ltd, operates an FDA-inspected sterile manufacturing facility with proven sterile injectable and ophthalmic R&D capabilities.
Stock Performance Snapshot
April 27, 2018 - At Friday's closing bell, Endo International's stock climbed 6.95%, ending the trading session at $6.00.
Volume traded for the day: 6.03 million shares, which was above the 3-month average volume of 5.10 million shares.
Stock performance in the last month – up 2.74%
After last Friday's close, Endo International's market cap was at $1.34 billion.
The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Other industry. This sector was up 0.4% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author"
and is fact checked and reviewed by a third-party research service company (the "Reviewer" represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor" , provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
Source: ACCESSWIRE Investor Awareness (April 30, 2018 - 7:40 AM EDT)
News by QuoteMedia
www.quotemedia.com
(0)
(0)Endo International plc (ENDPQ) Stock Research Links
Engineer by trade & Swing Trader at Heart!
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
Scroll down for more posts ▼